However, the effective NK/CIK-mediated killing of both the bulk and OCT4 + persistent cells following trabectedin-olaparib treatment, supports the therapeutic potential of this innovative sequential chemo–targeted–immune approach in advanced sarcomas and warrants further investigation. This evidence concerns the gene POU5F1 and sarcoma.